Goldman Sachs’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $171M | Buy |
1,965,432
+134,566
| +7% | +$13.1M | 0.02% | 745 |
|
|
2025
Q4 | $196M | Sell |
1,830,866
-62,797
| -3% | -$6.66M | 0.02% | 646 |
|
|
2025
Q3 | $191M | Buy |
1,893,663
+159,941
| +9% | +$14.8M | 0.02% | 623 |
|
|
2025
Q2 | $110M | Buy |
1,733,722
+95,814
| +6% | +$5.87M | 0.01% | 843 |
|
|
2025
Q1 | $86.8M | Sell |
1,637,908
-174,298
| -10% | -$9.67M | 0.01% | 855 |
|
|
2024
Q4 | $101M | Sell |
1,812,206
-2,067,590
| -53% | -$114M | 0.02% | 809 |
|
|
2024
Q3 | $203M | Sell |
3,879,796
-1,408,839
| -27% | -$67.5M | 0.03% | 516 |
|
|
2024
Q2 | $217M | Buy |
5,288,635
+177,034
| +3% | +$7.07M | 0.04% | 484 |
|
|
2024
Q1 | $221M | Buy |
5,111,601
+63,667
| +1% | +$2.79M | 0.04% | 456 |
|
|
2023
Q4 | $232M | Sell |
5,047,934
-112,607
| -2% | -$3.55M | 0.04% | 434 |
|
|
2023
Q3 | $118M | Sell |
5,160,541
-25,472
| -0.5% | -$570K | 0.03% | 635 |
|
|
2023
Q2 | $85.5M | Sell |
5,186,013
-124,690
| -2% | -$2.25M | 0.02% | 784 |
|
|
2023
Q1 | $94.7M | Buy |
5,310,703
+108,911
| +2% | +$2.74M | 0.02% | 719 |
|
|
2022
Q4 | $151M | Buy |
5,201,792
+424,614
| +9% | +$10.9M | 0.04% | 525 |
|
|
2022
Q3 | $117M | Buy |
4,777,178
+1,616,792
| +51% | +$30.1M | 0.03% | 605 |
|
|
2022
Q2 | $13.1M | Sell |
3,160,386
-179,364
| -5% | -$982K | ﹤0.01% | 2254 |
|
|
2022
Q1 | $38.5M | Buy |
3,339,750
+243,202
| +8% | +$2.13M | 0.01% | 1512 |
|
|
2021
Q4 | $30.9M | Buy |
3,096,548
+191,229
| +7% | +$2.15M | 0.01% | 1743 |
|
|
2021
Q3 | $37.9M | Buy |
2,905,319
+1,837,108
| +172% | +$28.1M | 0.01% | 1500 |
|
|
2021
Q2 | $20.9M | Buy |
1,068,211
+409,057
| +62% | +$8.49M | ﹤0.01% | 2012 |
|
|
2021
Q1 | $14M | Buy |
659,154
+606,742
| +1,158% | +$17.6M | ﹤0.01% | 2255 |
|
|
2020
Q4 | $1.56M | Sell |
52,412
-3,856
| -7% | -$98K | ﹤0.01% | 3905 |
|
|
2020
Q3 | $1.22M | Buy |
56,268
+23,195
| +70% | +$532K | ﹤0.01% | 3940 |
|
|
2020
Q2 | $738K | Sell |
33,073
-18,841
| -36% | -$367K | ﹤0.01% | 4153 |
|
|
2020
Q1 | $790K | Sell |
51,914
-12,927
| -20% | -$231K | ﹤0.01% | 3917 |
|
|
2019
Q4 | $1.49M | Buy |
64,841
+12,949
| +25% | +$288K | ﹤0.01% | 3864 |
|
|
2019
Q3 | $1.12M | Sell |
51,892
-3,952
| -7% | -$84.8K | ﹤0.01% | 3950 |
|
|
2019
Q2 | $1.23M | Buy |
55,844
+8,878
| +19% | +$224K | ﹤0.01% | 3862 |
|
|
2019
Q1 | $1.29M | Buy |
46,966
+26,935
| +134% | +$774K | ﹤0.01% | 3910 |
|
|
2018
Q4 | $538K | Buy |
20,031
+9,561
| +91% | +$264K | ﹤0.01% | 4326 |
|
|
2018
Q3 | $305K | Buy |
10,470
+2,952
| +39% | +$93.3K | ﹤0.01% | 4705 |
|
|
2018
Q2 | $235K | Buy |
+7,518
| New | +$206K | ﹤0.01% | 4922 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Goldman Sachs's RYTM Position: Q1 2026 in Review
Goldman Sachs increased its Rhythm Pharmaceuticals (RYTM) stake by 7.3% in Q1 2026, buying an estimated $13.1M and bringing the position to 1,965,432 shares worth $171M. The position accounts for 0.02% of the portfolio, ranked #745.
Goldman Sachs first reported a position in RYTM in Q2 2018 and has held it in 32 quarters since. The position peaked at $232M in Q4 2023. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Goldman Sachs held 1,965,432 shares of Rhythm Pharmaceuticals worth $171M as of Q1 2026.
- Goldman Sachs bought 134,566 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
- Rhythm Pharmaceuticals made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #745 holding.
- Goldman Sachs first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- Goldman Sachs's Rhythm Pharmaceuticals position peaked at $232M in Q4 2023.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.